| Before PSM | After PSM | ||||
---|---|---|---|---|---|---|
Variables | URY | RY | P†| URY | RY | P†|
N | 138 | 104 | Â | 88 | 88 | Â |
Age (years) | ||||||
 ≤ 60/ > 60 | 52/86 | 45/59 | 0.380 | 34/54 | 39/49 | 0.444 |
Gender | ||||||
 Female/male | 44/94 | 27/77 | 0.316 | 28/60 | 23/65 | 0.406 |
ASA | ||||||
 I–II/III | 103/35 | 84/20 | 0.260 | 67/21 | 73/15 | 0.262 |
Operative method | ||||||
 TLTG/TLDG | 65/73 | 35/69 | 0.035 | 32/56 | 35/53 | 0.641 |
T stage | ||||||
 T1–T2/T3–T4 | 72/66 | 37/67 | 0.010 | 30/58 | 32/56 | 0.752 |
LN metastasis | ||||||
 N0/N +  | 81/57 | 44/60 | 0.012 | 39/49 | 40/48 | 0.880 |
TNM | ||||||
 I + II/III | 98/40 | 51/53 | 0.001 | 48/40 | 46/42 | 0.762 |
Differentiation degree | ||||||
 High + medium/low | 70/68 | 64/40 | 0.094 | 47/41 | 48/40 | 0.880 |